News - Page 185 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article The World Boxing Council and Wesana Health Announce Multi-Year Joint Efforts to Research the Impact of Psychedelics on Traumatic Brain InjuryThe World Boxing Council and Wesana Health Announce Multi-Year Joint Efforts to Research the Impact of Psychedelics on Traumatic Brain Injury

The World Boxing Council and Wesana Health Announce Multi-Year Joint Efforts to Research the Impact of Psychedelics on Traumatic Brain InjuryThe World Boxing Council and Wesana Health Announce Multi-Year Joint Efforts to Research the Impact of Psychedelics on Traumatic Brain Injury

Post published:May 13, 2021
Post category:Press Release

Read more about the article Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Post published:May 13, 2021
Post category:Press Release

Read more about the article Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation

Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation

Post published:May 13, 2021
Post category:Press Release

Read more about the article MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

Post published:May 13, 2021
Post category:Press Release

Read more about the article Silo Wellness Partners with Kaivalya Kollectiv to Include 5-MeO-DMT In Psychedelic Portfolio Offering

Silo Wellness Partners with Kaivalya Kollectiv to Include 5-MeO-DMT In Psychedelic Portfolio Offering

Post published:May 12, 2021
Post category:Press Release

Read more about the article IntelGenx Expands Psychedelics Collaboration with atai Life Sciences with Signing of Second Feasibility Agreement

IntelGenx Expands Psychedelics Collaboration with atai Life Sciences with Signing of Second Feasibility Agreement

Post published:May 12, 2021
Post category:Press Release

Read more about the article IntelGenx Announces Shareholder Approval of atai Investment

IntelGenx Announces Shareholder Approval of atai Investment

Post published:May 11, 2021
Post category:Press Release

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

Post published:May 11, 2021
Post category:Press Release

Read more about the article CB Therapeutics Closes on Oversubscribed Series A

CB Therapeutics Closes on Oversubscribed Series A

Post published:May 10, 2021
Post category:Press Release

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD

Post published:May 10, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.